The Bruton’s Tyrosine Kinase inhibitors (BTKi) are a new class of medications being studied for use in both relapsing and progressive MS patients, and recent data published by one of…
Read More
The U.S. Food and Drug Administration (FDA) recently approved Tyruko (natalizumab-sztn, made by Sandoz, a division of the Novartis group). Tyruko is the first biosimilar disease-modifying therapy (DMT) for individuals…
What exactly is Progressive Multifocal Leukoencephalopathy (PML), other than a long and complicated phrase? How does one get it and what exactly is the risk of getting this with different…
Join RMMSC Medical Director Dr. Timothy Vollmer for an in-depth look at disease modifying therapies (DMTs) – the front line in our fight against MS. This webinar will give you…
The FDA officially approved Ocrelizumab (brand name: Ocrevus) for use in multiple sclerosis treatment on March 28, 2017. In this live Q&A, Dr. Enrique Alvarez answers some common questions on…
The FDA officially approved Ocrelizumab (brand name: Ocrevus) for use in multiple sclerosis treatment on March 28, 2017. In this live Q&A, Dr. Timothy Vollmer answers some common questions on…